TScan Therapeutics Inc. (NASDAQ:TCRX) does about 26.68K shares in volume on a normal day but saw 6066705 shares change hands in Monday trading. The company now has a market cap of 49.63M USD. Its current market price is $2.08, marking a decrease of -0.95% compared to the previous close of $2.10. The 52 week high reached by this stock is $5.60 whilst the lowest price level in 52 weeks is $1.45. The script in recent trading has seen the stock touch a high of $2.67 and a low of $1.95.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
TScan Therapeutics Inc. (TCRX) has a 20-day trading average at $1.83 and the current price is -62.84% off the 52-week high compared with 43.45% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.05 and its 200-day simple moving average is $2.76. If we look at the stock’s price movements over the week, volatility stands at 20.18%, which decreases to 17.09% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 53.57 to suggest the stock is neutral.
5 analysts observing the TScan Therapeutics Inc. (TCRX) stock have set the 12-month price targets for the company’s shares at between $6.00 and $21.00. The consensus objective for the share price is $14.00, suggesting that the stock has a potential upside of 85.14% over the period. The median price target is 85.66% away from the current levels at $14.50.
FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 4 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The current price level is 15.14%, 0.75%, and -24.78% away from its SMA20, SMA50, and SMA200 respectively, with the TCRX price moving above the 50-day SMA on January 23. TScan Therapeutics Inc. (TCRX) stock is down -5.45% over the week and 30.00% over the past month. Its price is 34.19% year-to-date and -55.93% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2022, with the company’s earnings per share (EPS) of -$0.63 above consensus estimates by $0.12. The company’s next earnings report is expected on 05/08/2023, with forecasts estimating quarterly EPS at -$0.72 and -$2.88 for whole year. TCRX’s earnings per share are forecast to grow by 30.90% this year and 1.00% over next year. Expected sales for next quarter are $3.88 million, which analysts say will come at $13.72 million for the current fiscal year and next year at $8.12 million. In addition, estimates put the company’s current quarterly revenue at an average of $3.7 million.
Its 12-month price target is $14.50. To reach the target analysts have set, the stock logically needs to grow 85.14 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $6.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $21.00.
Outstanding shares total 24.07M with insiders holding 12.69% of the shares and institutional holders owning 58.53% of the company’s common stock. The company has a return on investment of -30.20% and return on equity of -44.50%. Price to book ratio is 0.43 and price to sales ratio is 3.73.
